Search

everythinglearnresearchcommunity

for

Search:↓

Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.

Hormone replacement therapy may lower the risk of severe COVID-19 outcomes in non-immunosuppressed people and male organ transplant recipients.

Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.

COVID-19 can lead to different skin symptoms and might trigger autoimmune diseases in genetically susceptible people.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Hairless protein is key for hair growth, cell differences cause gene expression variation, and the N-end rule pathway senses nitric oxide for protein breakdown.

Long COVID patients may have hormonal imbalances linked to their symptoms.

Certain skin symptoms in COVID-19 patients may indicate a more severe illness.

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

People with hypohidrotic ectodermal dysplasia are more likely to experience long-term fatigue and hair loss after COVID-19.

Hair shedding after COVID-19 is more linked to the disease's severity and inflammation rather than hormones, with women at higher risk.

Androgens play a key role in causing alopecia by changing the hair growth cycle.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

The virus was not found in the semen and urine of a man who tested positive for COVID-19.

People with no symptoms or mild COVID-19 have lower antibody levels, increasing their risk of getting COVID-19 again.

COVID-19 can cause long-term skin problems and has changed how skin doctors work.

Men with androgenetic alopecia and hypertension may experience more severe COVID-19.

Enzymes are classified into six types and are essential for many biological processes, with only a few targeted by drugs.

Prostanoids, like prostaglandins and thromboxane A2, can both enhance and inhibit hair growth, and understanding their effects could help treat hair disorders.

Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.

Organoid technology is advancing and entering commercial use, with applications in disease modeling, drug development, and personalized medicine.

NF-κB signaling is crucial in many diseases and can be targeted for new treatments.

Hair loss doesn't affect COVID-19 severity.

5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.

Quercetin significantly helps hair growth by activating hair follicles and improving blood vessel formation around them.

Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

High doses of rosemary extract can harm the liver, kidneys, and reproductive organs in young rats.

Brown Adipose Tissue (BAT) could potentially treat Polycystic Ovary Syndrome (PCOS) by controlling energy balance and lipid homeostasis, but more human research is needed.

Sex hormones may affect COVID-19 severity, with estrogen possibly reducing risk and testosterone potentially increasing it.